INDOCO2023-04-012023-06-30 INDOCO2023-04-012023-06-30in-bse-fin:OneOperatingExpenses01Member INDOCO2023-04-012023-06-30in-bse-fin:OneOperatingExpenses02Member INDOCO2023-06-30 INDOCO2023-04-012023-06-30in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 532612 INDOCO NOTLISTED Indoco Remedies Limited Equity 2023-04-01 2024-03-31 2023-07-25 2023-07-14 INR Lakhs First quarter 10:30:00 11:30:00 2023-07-25 2023-07-25 Not applicable Single segment PHARMACEUTICALS 2023-04-01 2023-06-30 Unaudited Standalone 4228800000.00 4100000.00 4232900000.00 996200000.00 321300000.00 -56800000.00 903200000.00 77800000.00 198700000.00 1435800000.00 3876200000.00 356700000.00 0.00 356700000.00 85500000.00 11800000.00 97300000.00 0.00 259400000.00 0.00 0.00 0.00 0.00 259400000.00 -2300000.00 257100000.00 0.00 0.00 184300000.00 2 2.81 2.81 0.00 0.00 2.81 2.81 1. The unaudited Standalone Results for the Quarter ended 30th June, 2023 have been reviewed by the Audit committee and approved by the Board of Directors of the Company at its meeting held on 25th July, 2023. The Statutory Auditors have expressed an Unmodified Audit opinion on these unaudited Standalone Financial Results 2. The figures for corresponding previous periods have been restated / regrouped wherever necessary, to make them comparable. 3. The company has only one primary reportable segment of activity, namely, Pharmaceuticals. 4. Net Sales and Income from Operations as per Secondary Segment (Geographical) is as follows: Net Sales Quarter ended Quarter ended Quarter ended Year ended and Income 30.06.2023 31.03.2023 30.06.2022 31.03.2023 from (Unaudited) (Audited) (Unaudited) (Audited) Operations --------------------------------------------------------------------------------------------------------------------------- India 23,055 20,228 20,666 84,787 Outside India 18,264 22,577 18,823 79,026 Total 41,319 42,805 39,489 1,63,813 ============================================================ 5. The statutory auditors of the company have carried out limited review of the financial results for the quarter ended 30th June, 2023. 6. Figures for the quarter ended 31.3.2023 represents the difference between audited figures in respect of the full financial year and published figures for the period ended 31.12.2022 (limited reviewed). 7. There are no Exceptional Items OTHER EXPENSES 1197000000.00 RESEARCH & DEVELOPMENT EXPENSES 238800000.00 ITEMS THAT WILL NOT BE RECLASSIFIED TO PROFIT AND LOSS -3000000.00 -3000000.00 -700000.00 0.00